Abstract
The clinical relevance of bax and bcl-2 protein expression has been investigated in 84 patients with recurrent or metastatic colorectal cancer submitted to a chemotherapy regimen including methotrexate and fluorouracil/leucovorin. Cytoplasmic immunostaining of bax and bcl-2 was present in 65.5% and 38%, respectively, of the tumours. No association was found between bax and bcl-2 or between p53 and bax or bcl-2 protein expression. Moreover, the biomarkers were unrelated to patient and tumour characteristics known to affect the clinical outcome of colorectal cancer patients. In general, the apoptosis-related markers did not appear indicative of short- and long-term clinical response nor of prognosis. Bcl-2-negative lesions were more frequent among patients who reached an objective clinical response, which is in agreement with previously reported data regarding other tumour types. When the interrelationship between p53 and bax expression was examined, a better response rate (40%) was found for patients whose tumours did not express p53 and bax, and a better prognosis (2-year probability of overall survival 75%) for patients with p53-positive and bax-negative tumours. In the present series of patients with advanced colorectal cancer submitted to systemic chemotherapy we did not find a clear association between expression of apoptosis-related markers and clinical outcome, even in the subset of patients in which the apoptotic index as determined by the TUNEL approach was investigated. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abdel-Rahman WM, Georgiades IB, Curtis LJ, Arends MJ and Wyllie AH (1999) Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis. Oncogene 18: 2139–2142
Apolinario RM, Van Der Valk P, De Jong JS, Deville W, Van Ark-Otte J, Dingemans AMC, Van Mourik JC, Postmus PE, Pinedo HM and Giaccone G (1997) Prognostic value of the expression of p53, bcl-2 and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15: 2456–2466
Barretton BG, Diebold J, Christoforis G, Vogt M, Müller C, Dopfer K, Schneiderbanger K, Schmidt M and Löhrs U (1996) Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 77: 255–264
Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD and Dorken B (1995) Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60: 854–859
Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD and Dorken B (1996) Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Investigation 97: 2651–2659
Berney CR, Downing SR, Yang J-L, Russell PJ and Crowe PJ (2000) Evidence for post-transcriptional down-regulation of the apoptosis-related gene bcl-2 in human colorectal cancer. J Pathol 191: 15–20
Bonetti A, Zaninelli M, Leone R, Cetto GL, Pelosi G, Biolo S, Menghi A, Manfrin E, Bonetti F and Piubello Q (1998) bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 4: 2331–2336
Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC and Wyllie AH (1996) Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 12: 2641–2649
Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP and Guyotat D (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81: 3091–3096
Clark JW (1997) Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. Semin Oncol 24: s18–24
Costa A, Marasca R, Valentinis B, Savarino M, Faranda A, Torelli G and Silvestrini R (1995) p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 176: 45–53
Costa A, Doci R, Mochen C, Bignami P, Faranda A, Gennari L and Silvestrini R (1997) Cell proliferation-related markers in colorectal liver metastases: correlation with patient prognosis. J Clin Oncol 15: 2008–2014
Costa A, Licitra L, Veneroni S, Daidone MG, Grandi C, Cavina R, Molinari R and Silvestrini R (1998) Biological markers as indicators of pathological response to primary chemotherapy in oral cavity cancers. Int J Cancer 79: 619–623
Daidone MG, Veneroni S, Benini E, Tomasic G, Coradini D, Mastore M, Brambilla C, Ferrari L and Silvestrini R (1999) Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer 84: 580–586
De Angelis PM, Stokke T, Thorstensen L, Lothe RA and Clausen OPF (1998) Apoptosis and expression of bax, bcl-x, and bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and associations with p53 genotype/phenotype. J Clin Pathol: Mol Pathol 51: 254–261
Dive C and Hickman JA (1991) Drug-target interactions: only the first step in the commitment to a programmed cell death?. Br J Cancer 64: 192–196
Eastman A (1990) Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275–280
Farczadi E, Szanto J, Kaszas I, Benyo I, Bodnar Z, Szlobodnyik J and Szende B (1999) Changes in apoptotic and mitotic activity in rectal carcinoma after short-term cytostatic therapy as possible predictive factors. Neoplasma 46: 219–223
Forster S, Sattler HP, Hack M, Romanakis K, Rohde V, Seitz G and Wullich B (1998) Microsatellite instability in sporadic carcinomas of the proximal colon: association with diploid DNA content, negative protein expression of p53, and distinct histomorphologic features. Surgery 123: 13–18
Fracchiolla NS, Capaccio P, Carboni N, Pagliari AV, Neri A, Ronchett D, Pruner G, Silvotti MG, Pignataro L, Buffa R and Broich G (1999) Immunohistochemical and molecular analysis of bax, bcl-2 and p53 genes in laryngeal squamous cell carcinomas. Anticancer Res 19: 1043–1052
Gasparini G, Bevilacqua P, Bonoldi E, Testolini A, Galassi A, Verderio P, Boracchi P, Guglielmi RB and Pezzella F (1995) Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1: 1375–1383
Gavrieli Y, Sherman Y and Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493–501
Hall PA (1999) Assessing apoptosis: a critical survey. Endocrine-Related Cancer 6: 3–8
Homma A, Furuta Y, Oridate N, Nakano Y, Dohashi G, Yagi K, Nagahashi T, Fukuda S, Inoue K and Inuyama Y (1999) Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 5: 801–806
Johnston PG, Liang CM, Henry S, Chabner BA and Allegra CJ (1991) Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissues. Cancer Res 51: 6668–6676
Kawasaki H, Altieri DC, Lu C-D, Toyoda M, Tenjo T and Tanigawa N (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071–5074
Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius V-M, Niskanen E, Nordling S and Reed JC (1995) Reduced expression of pro-apoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471–4478
Langlois NE, Lamb J, Eremin O and Heys SD (1997) Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c-myc and bcl-2 products. J Pathol 182: 392–397
Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Chien CT and Wang SM (1999) Clinicopathologic and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection. Hepato-Gastroenterol 46: 883–890
Lukish JR, Muro K, DeNobile J, Katz R, Williams J, Cruess DF, Drucker W, Kirsch I and Hamilton SR (1998) Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 227: 51–56
Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Perez JE, Rodriquez R, Cuevas MA, Alvarez LA, Chacon R and Hannois A (1991) Advanced colorectal carcinoma. Am J Clin Oncol 14: 211–217
Matsuura T, Fukuda Y, Fujitaka T, Nishisaka T, Sakatani T and Ito H (2000) Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma. Cancer 88: 1007–1015
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM and Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940–6944
Nelson NJ (1998) Quest for new and better colon cancer treatments picks up steam. J Natl Cancer Inst 90: 1858–1859
Newland RC, Dent OF, Lyttle MNB, Chapius PH and Bokey EL (1994) Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. Cancer 73: 2076–2082
Öfner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Tötsch M, Böcker W, Jasani B and Schmid KW (1995) Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 72: 981–985
Ogura E, Senzaki H, Yamamoto D, Yoshida R, Takada H, Hioki K and Tsubura A (1999) Prognostic significance of bcl-2, bcl-xL/S, bax and bak expressions in colorectal carcinomas. Oncol Reports 6: 365–369
Orlandi L, Bearzatto A, Abolafio G, De Marco C, Daidone MG and Zaffaroni N (1999) Involvement of bcl-2 and p21 waf1 proteins in response of human breast cancer cell clones to Tomudex. Br J Cancer 81: 252–260
Paradiso A, Rabinovich M, Vallejo C, Machaivelli M, Romero A, Perez J, Lacava J, Cuevas MA, Rodriquez R, Leone B, Sapia MG, Simone G and De Lena M (1996) p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer 69: 437–441
Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ and Johnston PG (2000) Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer. Br J Cancer 82: 560–567
Petrelli NJ (1995) It is time to stratify with prognostic factors for hepatic metastases. J Clin Oncol 13: 2471–2472
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC and Perucho M (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967–969
Schmitt CA and Lowe S (1999) Apoptosis and therapy. J Pathol 187: 136–149
Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G and Veronesi U (1994) bcl-2, a prognostic indicator strongly related to p53 in node-negative breast cancer. J Natl Cancer Inst 86: 499–504
Silvestrini R, Daidone MG, Veneroni S, Benini E, Scarfone G, Zanaboni F, Villa A, Presti M, Danese S and Bolis G (1998) The clinical predictivity of biomarkers of stage III–IV epithelial ovarian cancers in a prospective randomized treatment protocol. Cancer 82: 159–167
Sionov RV and Haupt Y (1999) The cellular response to p53: the decision between life and death. Oncogene 18: 6145–6157
Sturm E, Köhne C-H, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B and Daniel PT (1999) Analysis of the p53/bax pathway in colorectal cancer: low bax is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17: 1364–1374
Sugamura K, Makino M and Kaibara N (1998) Apoptosis as a prognostic factor in colorectal carcinoma. Surgery Today 28: 145–150
Sugura K, Makino M, Shirai H, Kimura O, Maeta M, Itoh H and Kaibara N (1997) Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. Cancer 79: 12–17
Tai Y-T, Lee S, Niloff E, Weisman C, Strobel T and Cannistra SA (1998) Bax protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 16: 2583–2590
Takano Y, Saegusa M, Ikenaga M, Mitomi H and Okayasu I (1996) Apoptosis of colon cancer: comparison with Ki-67 proliferative activity and expression of p53. J Cancer Res Clin Oncol 122: 166–170
Tang R, Wang YJ, Chen JS, Chang-Chien CR, Tang S, Lin SE, You YT, Hsu KC, Ho YS and Fan HA (1995) Survival impact of lymph node metastasis in TNM stage II carcinoma of the colon and rectum. J Am Coll Surg 180: 705–712
Tannapfel A, Nusslein S, Fietkau R, Katalinic A, Kockerling F and Wittekind C (1998) Apoptosis, cell proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 41: 585–591
Teixeira C, Reed JC and Pratt MA (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902–3907
Tenjo T, Toyoda M, Okuda J, Wtanabe I, Yamamoto T, Tanaka K, Ohtani M, Nohara T, Kawasaki H and Tanigawa N (2000) Prognostic significance of p27kip1protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 58: 45–51
Yamane N, Makino M and Kaibara N (1999) S-phase accumulation precedes apoptosis induced by preoperative treatment with 5-fluorouracil in human colorectal carcinoma cells. Cancer 85: 309–317
Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM and Frizzera G (1989) bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. New Engl J Med 320: 1047–1054
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Paradiso, A., Simone, G., Lena, M. et al. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer 84, 651–658 (2001). https://doi.org/10.1054/bjoc.2000.1658
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1658
Keywords
This article is cited by
-
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients
Clinical and Translational Oncology (2013)
-
Role of BAX for outcome prediction in gastrointestinal malignancies
Medical Oncology (2013)
-
Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis
International Journal of Colorectal Disease (2006)
-
Chemotherapy: targeting the mitochondrial cell death pathway
Oncogene (2002)